This Article Full Text Full Text (PDF) Other Versions of this Article: JVI.01404-06v1 81/1/362    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Balzarini, J. Articles by Schols, D. Search for Related Content PubMed PubMed Citation Articles by Balzarini, J. Articles by Schols, D.

Pradimicin A, a Carbohydrate-Binding Nonpeptidic Lead Compound for Treatment of Infections with Viruses with Highly Glycosylated Envelopes, Such as Human Immunodeficiency Virus

Rega Institute for Medical Research, K.U. Leuven, B-3000 Leuven, Belgium,¹ Department of Biomedical Sciences and Biotechnology, University of Brescia, I-25123 Brescia, Italy,² Biotechnology Research Center, Toyama Prefectural University, Kurokawa 5180, Kosugi, Imizu-shi, Toyama 939-0398, Japan,³ Keck School of Medicine, University of Southern California, Los Angeles, California⁴

Received 5 July 2006/ Accepted 6 October 2006

Pradimicin A (PRM-A), an antifungal nonpeptidic benzonaphtacenequinone antibiotic, is a low-molecular-weight (molecular weight, 838) carbohydrate binding agent (CBA) endowed with a selective inhibitory activity against human immunodeficiency virus (HIV). It invariably inhibits representative virus strains of a variety of HIV-1 clades with X4 and R5 tropisms at nontoxic concentrations. Time-of-addition studies revealed that PRM-A acts as a true virus entry inhibitor. PRM-A specifically interacts with HIV-1 gp120 and efficiently prevents virus transmission in cocultures of HUT-78/HIV-1 and Sup T1 cells. Upon prolonged exposure of HIV-1-infected CEM cell cultures, PRM-A drug pressure selects for mutant HIV-1 strains containing N-glycosylation site deletions in gp120 but not gp41. A relatively long exposure time to PRM-A is required before drug-resistant virus strains emerge. PRM-A has a high genetic barrier, since more than five N-glycosylation site deletions in gp120 are required to afford moderate drug resistance. Such mutated virus strains keep full sensitivity to the other known clinically used anti-HIV drugs. PRM-A represents the first prototype compound of a nonpeptidic CBA lead and, together with peptide-based lectins, belongs to a conceptually novel type of potential therapeutics for which drug pressure results in the selection of glycan deletions in the HIV gp120 envelope.

Published ahead of print on 18 October 2006.

This article has been cited by other articles:

• Francois, K. O., Auwerx, J., Schols, D., Balzarini, J. (2008). Simian Immunodeficiency Virus Is Susceptible to Inhibition by Carbohydrate-Binding Agents in a Manner Similar to That of HIV: Implications for Further Preclinical Drug Development. Mol. Pharmacol. 74: 330-337 [Abstract] [Full Text]  
• van der Meer, F. J. U. M., de Haan, C. A. M., Schuurman, N. M. P., Haijema, B. J., Verheije, M. H., Bosch, B. J., Balzarini, J., Egberink, H. F. (2007). The carbohydrate-binding plant lectins and the non-peptidic antibiotic pradimicin A target the glycans of the coronavirus envelope glycoproteins. J Antimicrob Chemother 60: 741-749 [Abstract] [Full Text]